Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 30, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Wells Fargo Healthcare Conference at 4:10 PM EDT on...
-
Aug 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug Administration for the store brand OTC equivalent of Nexium® 24HR...
-
Aug 16, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Aug 10, 2017
Delivered second quarter 2017 GAAP ("reported") net sales of $1.2 billion CHC Americas segment reported nets sales of $605 million compared to $630 million last year, lower by 4%; Adjusted net...
-
Aug 8, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on September 12, 2017 to shareholders of record on...
-
Aug 4, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Mirvaso® (brimonidine) topical gel...
-
Jul 31, 2017
Perrigo Company plc (NYSE; TASE: PRGO) and its co-development partner Aveva Drug Delivery Systems, Inc., an Apotex Company, today announced the prescription pharmaceutical launch of scopolamine...
-
Jul 27, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter 2017 financial results on Thursday, August 10, 2017. The Company will conduct a conference call at...
-
Jul 19, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Jul 17, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that its subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic...
-
Jul 17, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Jul 17, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled the Hatch-Waxman litigation relating to Dymista® (azelastine hydrochloride and fluticasone propionate) nasal spray...
-
Jul 5, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced the prescription pharmaceutical launch of testosterone topical solution, 30 mg/1.5 mL (CIII), the generic equivalent to Eli Lilly and...
-
Jun 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality Affordable Healthcare Products®", today announced that the Company's Board of Directors has retained Spencer Stuart,...
-
Jun 21, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%)...
-
Jun 19, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched hydrocodone bitartrate and homatropine methylbromide oral solution. Hydrocodone bitartrate and homatropine methylbromide oral...
-
Jun 14, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the reference yield and total consideration for each series of notes subject to the previously announced cash...
-
Jun 14, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Jeff Needham, Perrigo's Executive Vice President and President, Consumer Healthcare Americas, will present at the Oppenheimer 2017...
-
Jun 14, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today the early tender results as of 5:00 p.m., New York City time, June 13, 2017 (the "Early Tender Deadline") for...
-
Jun 5, 2017
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality Affordable Healthcare Products®, today announced the forthcoming retirement of Chief Executive Officer John T....
-
Jun 2, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo CEO John T. Hendrickson will present at the Jefferies 2017 Healthcare Conference at 3:00 PM EDT on Tuesday, June 6, 2017....
-
May 31, 2017
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) announced today that it and Perrigo Finance Unlimited Company, its wholly-owned finance subsidiary ("Perrigo Finance"), have...
-
May 30, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Wednesday, May 31 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer,...
-
May 30, 2017
Delivered first quarter 2017 GAAP ("reported") net sales of $1.2 billion, led by consumer-facing businesses net sales of $958 million Realized first quarter reported net income of $72 million and...
-
May 22, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will conduct a conference call on Tuesday, May 23 at 8:30AM (ET) hosted by John T. Hendrickson, Perrigo's Chief Executive Officer, to...